CDK9 and neoplasm: AZD4573 (AstraZeneca) is another highly potent CDK9 inhibitor with >25-fold selectivity for CDK9 over other CDKs; it has demonstrated broad anti-tumour activity in preclinical studies and in a clinical trial of relapsed haematological malignancies (NCT03263637) [182,183].